• Discordant amyloid-β PET and CSF biomarkers and its clinical consequencesWilde, Arno de; Reimand, Juhan; Teunissen, Charlotte E.; Zwan, MarissaAlzheimer's Research & Therapy2019 / art. 78, 13 p. : ill https://doi.org/10.1186/s13195-019-0532-x https://www.scopus.com/sourceid/19700174935 https://www.scopus.com/record/display.uri?eid=2-s2.0-85072103935&origin=inward&txGid=bf3373ff7d55788a6c63ff3815f91f87 https://jcr.clarivate.com/jcr-jp/journal-profile?journal=ALZHEIMERS%20RES%20THER&year=2022 https://www.webofscience.com/wos/woscc/full-record/WOS:000485872800001
• Why is amyloid-β PET requested after performing CSF biomarkers?Reimand, Juhan; Groot, Colin; Teunissen, Charlotte E.; Windhorst, Albert D.; Boellaard, Ronald; Barkhof, Frederike; Nazarenko, Sergei; van der Flier, Wiesje M.; Scheltens, Philip; Ossenkoppele, Rik; Bouwman, FemkeJournal of Alzheimer's disease2020 / p. 559-569 https://doi.org/10.3233/JAD-190836 https://www.scopus.com/sourceid/16246 https://www.scopus.com/record/display.uri?eid=2-s2.0-85078507057&origin=inward&txGid=00d41882032da9684bcf6453fabe39df https://jcr.clarivate.com/jcr-jp/journal-profile?journal=J%20ALZHEIMERS%20DIS&year=2022 https://www.webofscience.com/wos/woscc/full-record/WOS:000512318900012